New Paper: Early and long-term immune response to mRNA vaccines in 5–11 years old children

24.03.2024 A recent study of our ORCHESTRA partners has explored early and long-term immune response to mRNA vaccines in children. Precisely, 5–11 years old children attending the University Pediatric Hospital of Padua and Bambino-Gesù Hospital in Rome (Italy), vaccinated with the Pfizer BioNTech (BNT162b2) mRNA vaccine, were investigated in immune response pre-, 1-, and 6-months after vaccination.

 

mRNA vaccination triggered a higher production of specific anti-SARS-CoV-2 antibodies along with increased levels of regulatory cells in children with previous SARS-CoV-2 infection up to the following 6 months. These findings provide insights into boosting pre-existing immunity.

 

More about the study here: https://www.sciencedirect.com/science/article/pii/S0264410X23014391